Clinical responses during gold therapy for rheumatoid arthritis. changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities, Arthritis & Rheumatism, vol.7, issue.5, pp.540-549, 1982. ,
DOI : 10.1001/jama.1962.03050340001001
Bowel Damage as Assessed by the L??mann Index is Reversible on Anti-TNF Therapy for Crohn???s Disease, Journal of Crohn's and Colitis, vol.25, issue.8, pp.633-642, 2015. ,
DOI : 10.1097/00054725-200207000-00002
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn???s Disease and its Impact on Disease Outcome, Journal of Crohn's and Colitis, vol.doi, pp.10-1093, 2016. ,
DOI : 10.1038/ajg.2016.177
Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment, Arthritis Care & Research, vol.39, issue.Suppl 39, pp.4-13, 2011. ,
DOI : 10.3109/03009740903447044
Measurement of patient outcome in arthritis, Arthritis & Rheumatism, vol.33, issue.2, pp.137-182, 1980. ,
DOI : 10.1001/jama.1963.03060120024016
The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation, J Rheumatol, vol.30, pp.167-78, 2003. ,
ICF Core Sets for rheumatoid arthritis, Journal of Rehabilitation Medicine, vol.36, issue.0, pp.87-93, 2004. ,
DOI : 10.1080/16501960410015470
Validation of the comprehensive ICF Core Set for rheumatoid arthritis: the perspective of physicians, J Rehabil Med, vol.42, pp.780-788, 2010. ,
Validation of the Comprehensive ICF Core Set for rheumatoid arthritis: The perspective of psychologists, Psychology & Health, vol.44, issue.6, pp.639-59, 2008. ,
DOI : 10.1111/j.1365-2648.1994.tb01066.x
Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study, Clin Exp Rheumatol, vol.24, issue.6, 2006. ,
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial, Gut, vol.140, issue.(Suppl 1), pp.88-95, 2014. ,
DOI : 10.1016/j.cgh.2012.03.026
Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease, Journal of Crohn's and Colitis, vol.50, issue.A-146, pp.477-83, 2011. ,
DOI : 10.1016/S0016-5107(99)80017-0
Deep Remission: A New Concept?, Digestive Diseases, vol.358, issue.s3, pp.107-118, 2012. ,
DOI : 10.1056/NEJMoa0802743
URL : http://orbi.ulg.ac.be/bitstream/2268/138986/1/2012-Deep%20Remission%20-%20A%20New%20Concept-DigDis-Pr%c3%a9PA.pdf
analysis, Alimentary Pharmacology & Therapeutics, vol.12, issue.Suppl. 1, pp.734-780, 2015. ,
DOI : 10.1016/j.cgh.2014.02.016
URL : https://hal.archives-ouvertes.fr/hal-01605208
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1362, 2015. ,
DOI : 10.1038/ajg.2012.117
URL : https://hal.archives-ouvertes.fr/hal-01191653
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases, Gastroenterology, vol.152, issue.2, pp.351-61, 2017. ,
DOI : 10.1053/j.gastro.2016.09.046
Very recent onset arthritis? clinical, laboratory, and radiological findings during the first year of disease, J Rheumatol, vol.29, pp.2278-87, 2002. ,
Early Undifferentiated Arthritis, Rheumatic Disease Clinics of North America, vol.31, issue.4, pp.605-631, 2005. ,
DOI : 10.1016/j.rdc.2005.07.006
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis & Rheumatism, vol.143, issue.3, pp.315-339, 1988. ,
DOI : 10.1002/art.1780310302
Current evidence for a strategic approach to the management of rheumatoid arthritis with diseasemodifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis ,
Drug management of early rheumatoid arthritis ??? 2008, Best Practice & Research Clinical Rheumatology, vol.23, issue.1, pp.93-102, 2009. ,
DOI : 10.1016/j.berh.2008.08.003
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Arthritis Care & Research, vol.49, issue.Suppl, pp.1-25, 2015. ,
DOI : 10.1093/rheumatology/keg072
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease, Annals of the Rheumatic Diseases, vol.67, issue.Suppl 10, pp.1268-71, 2016. ,
DOI : 10.1002/art.39322
SP0183???2016 Update of The EULAR Recommendations for The Management of Early Arthritis, Annals of the Rheumatic Diseases, vol.75, issue.Suppl 2, p.44, 2016. ,
DOI : 10.1136/annrheumdis-2016-eular.6370
What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review, Annals of the Rheumatic Diseases, vol.20, issue.S, pp.861-70, 2014. ,
DOI : 10.1093/rheumatology/keq424
Clinics, Annals of the Rheumatic Diseases, vol.47, issue.8, pp.1295-301, 2013. ,
DOI : 10.1093/rheumatology/ken031
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis & Rheumatism, vol.61, issue.Suppl 31, pp.2569-81, 2010. ,
DOI : 10.7326/0003-4819-124-8-199604150-00001
URL : https://hal.archives-ouvertes.fr/hal-01557559
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data, The American Journal of Gastroenterology, vol.102, issue.7, pp.1574-82, 2010. ,
DOI : 10.1016/S0140-6736(08)60304-9
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease, Gastroenterology, vol.113, issue.1, pp.118-144, 1997. ,
DOI : 10.1016/S0016-5085(97)70116-1
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease, Gut, vol.56, issue.12, pp.1696-705, 2007. ,
DOI : 10.1136/gut.2006.116467
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process, The American Journal of Gastroenterology, vol.12, issue.1, pp.1770-1776, 2012. ,
DOI : 10.1053/j.gastro.2005.12.019
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis, Rheumatology, vol.43, issue.7, pp.906-920, 2004. ,
DOI : 10.1093/rheumatology/keh199
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn???s Disease: An IOIBD Initiative, Journal of Crohn's and Colitis, vol.39, issue.8, pp.601-607, 2015. ,
DOI : 10.1136/annrheumdis-2012-201777
URL : https://hal.archives-ouvertes.fr/hal-01668612
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, The Lancet, vol.371, issue.9613, pp.660-667, 2008. ,
DOI : 10.1016/S0140-6736(08)60304-9
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial, The Lancet, vol.386, issue.10006, pp.1825-1859, 2015. ,
DOI : 10.1016/S0140-6736(15)00068-9
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care & Research, vol.42, issue.Suppl, pp.625-664, 2008. ,
DOI : 10.1093/rheumatology/keg072
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs, British Journal of Clinical Pharmacology, vol.3, issue.2 ,
DOI : 10.7326/0003-4819-146-6-200703200-00005
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.914-935, 2009. ,
DOI : 10.1136/ard.2008.092254
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial, The Lancet, vol.372, issue.9636, pp.375-82, 2008. ,
DOI : 10.1016/S0140-6736(08)61000-4
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Arthritis & Rheumatism, vol.340, issue.11, pp.3319-3348, 2008. ,
DOI : 10.7326/0003-4819-130-6-199903160-00004
Disease-Modifying Anti-Inflammatory Bowel Disease Drugs (DMAIDs): The Missing Term in the Literature, The American Journal of Gastroenterology, vol.9, issue.5, pp.859-60, 2013. ,
DOI : 10.1056/NEJM200011303432202
URL : https://hal.archives-ouvertes.fr/hal-01701193
Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial, Gastroenterology, vol.145, issue.4, pp.758-65, 2013. ,
DOI : 10.1053/j.gastro.2013.04.048
Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease, Gastroenterology, vol.145, issue.4, pp.766-74, 2013. ,
DOI : 10.1053/j.gastro.2013.06.009
Early Combined Immunosuppression in Crohn???s Disease: Acting Rather Than REACTing, Gastroenterology, vol.150, issue.4, pp.1040-1041, 2016. ,
DOI : 10.1053/j.gastro.2016.02.056
URL : https://hal.archives-ouvertes.fr/hal-01666729
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases, Journal of Crohn's and Colitis, vol.19, issue.12, pp.660-667, 2016. ,
DOI : 10.1007/s00535-012-0603-2
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations, Journal of Crohn's and Colitis, vol.1, issue.Suppl 2, pp.63-101, 2010. ,
DOI : 10.1001/jama.299.14.1690
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?, Nature Reviews Gastroenterology & Hepatology, vol.60, issue.6, pp.345-51, 2013. ,
DOI : 10.1136/gutjnl-2011-300934
Clinical Risk Factors for Complicated Disease: How Reliable Are They?, Digestive Diseases, vol.59, issue.s3, pp.67-72, 2012. ,
DOI : 10.1136/gutjnl-2011-300049
Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, Arthritis & Rheumatism, vol.39, issue.5, pp.1401-1410, 2006. ,
DOI : 10.1148/85.2.325
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort, Annals of the Rheumatic Diseases, vol.71, issue.5, pp.681-687, 2012. ,
DOI : 10.1136/ard.2011.154625
Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease, Gastroenterology, vol.149, issue.7, pp.1716-1746, 2015. ,
DOI : 10.1053/j.gastro.2015.08.055
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions, Clinical Gastroenterology and Hepatology, vol.14, issue.3, pp.348-54, 2016. ,
DOI : 10.1016/j.cgh.2015.06.001
URL : https://hal.archives-ouvertes.fr/hal-01668509
Development of an index to define overall disease severity in IBD, Gut, vol.67, issue.2, pp.10-1136, 2016. ,
DOI : 10.1136/gutjnl-2016-312648